Saurabh Upadhyay

This study shows that stabilizing the CHI3L1-Gal3BP complex with LZ6 improves the glioblastoma immune microenvironment and extends survival, both alone and when combined with PD-1 blockade.

The paper identifies CHI-DEL, a brain-penetrant CHI3L1 inhibitor, and validates its on-target effects using genetic rescue experiments and in vivo models of glioblastoma.

This paper identifies DELC2, a brain-penetrant CHI3L1 inhibitor, which reduces neuroinflammation and amyloid-β levels in Alzheimer's disease models.

A CD28-selective small molecule blocks pathogenic T cell activation and preserves Treg function unlike Abatacept in IBD models.

This study uses AI-enhanced virtual screening to identify potent CD28 binders from a large chemical library, achieving submicromolar affinity and functional blockade.

This paper designs AI-generated cyclic peptides that modulate the CD28 immune checkpoint with controllable pharmacology and therapeutic efficacy in preclinical models.

This study introduces CP8, a cyclic peptide that effectively blocks CD28 co-stimulation and allows rapid restoration of T-cell function, outperforming existing biologics under exposure-limited conditions.

As48 is a small molecule that activates TREM2 and inhibits its shedding, offering a dual mechanism to enhance microglial function in Alzheimer's disease.

HTS-Oracle uses AI to prioritize small molecule hits for challenging immune targets, reducing screening needs and increasing hit rates significantly.

This paper identifies two small molecule CD28 inhibitors using AS-MS and validates their ability to block CD28-B7 interactions and suppress T cell activation in co-culture models.

This paper develops an SPR-based HTS workflow to identify CD28-targeted small molecules, finding three compounds with micromolar affinities and functional inhibition of CD28-CD80 interaction.

This study identifies BPU11, a small molecule CD28 antagonist that disrupts CD28-B7 interactions and suppresses T-cell activation, offering a new approach to immune checkpoint blockade.

HTS-Oracle improves hit identification for difficult-to-drug targets by using a deep learning platform that integrates molecular embeddings and cheminformatics features, achieving an 8.4% hit rate with reduced screening costs.

This paper identifies a novel druggable site on CD28 and discovers 22VS, a small molecule inhibitor that suppresses T cell activation in co-culture models, with favorable pharmacokinetic properties.